Does Mounjaro protect your heart? What the FDA approval really means

On 28 August 2026 the FDA approved Mounjaro (tirzepatide) to lower the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes and high cardiovascular risk. It is the first GIP/GLP-1 drug to earn a heart indication, and the coverage has been loud. The trial underneath the approval tells a more careful story: Mounjaro matched an older heart-protective drug, it did not clearly beat it.

The short answer

Yes, Mounjaro now carries an FDA heart indication, but only for people with type 2 diabetes who already have cardiovascular disease or are at high risk of it. The approval rests on a trial called SURPASS-CVOT, which pitted tirzepatide against dulaglutide (Trulicity), another GLP-1 that was already proven to protect the heart. Tirzepatide was as good as dulaglutide. It was not shown to be better, and it is not approved for heart protection in anyone without type 2 diabetes.

What the FDA actually approved

The new label lets Mounjaro be prescribed to reduce major adverse cardiovascular events (doctors call this MACE, meaning cardiovascular death, non-fatal heart attack and non-fatal stroke) in adults who have both type 2 diabetes and established cardiovascular disease or a high risk of it. That makes tirzepatide the fourth indication for Mounjaro and puts it level with Ozempic (semaglutide), which has held a cardiovascular label since 2020.

The wording matters more than most headlines let on. This is a type 2 diabetes indication. If you take Mounjaro or Zepbound purely for weight loss and do not have diabetes, this approval does not apply to you, and the trial behind it did not study you. Nobody should read "Mounjaro protects the heart" as a green light to start, stop or switch a medication on their own.

Inside SURPASS-CVOT: matched, not beat

SURPASS-CVOT was a large, well-run trial published in the New England Journal of Medicine. It enrolled 13,299 adults who had type 2 diabetes plus atherosclerotic cardiovascular disease, then randomly assigned them to weekly tirzepatide (up to 15 mg, 6,586 people) or weekly dulaglutide (1.5 mg, 6,579 people) and followed them for a median of nearly four years. The average participant was 64 years old, had lived with diabetes for almost 15 years, and started with an HbA1c of 8.4%.

Here is the design choice that changes how you should read the result. This was not tirzepatide versus a placebo. It was tirzepatide versus dulaglutide, a GLP-1 that had already earned its own heart indication years earlier. So the trial was not asking "does tirzepatide beat a sugar pill?" It was asking "is tirzepatide at least as good as a drug we already trust for the heart?"

Primary heart outcome (MACE)	Tirzepatide (Mounjaro)	Dulaglutide (Trulicity)
People with a heart attack, stroke or CV death	801 of 6,586 (12.2%)	862 of 6,579 (13.1%)
Hazard ratio (95.3% CI)	0.92 (0.83 to 1.01)
P value for non-inferiority	0.003 (met)
P value for superiority	0.09 (not met)

Read the bottom two rows together. The trial met its goal of showing tirzepatide was non-inferior, meaning as good as dulaglutide (P=0.003). It did not meet the higher bar of superiority, meaning clearly better (P=0.09). The 8% relative reduction you may see quoted comes from that hazard ratio of 0.92, but its confidence interval crosses 1.0, so statistically the result is "a tie, in tirzepatide's favour" rather than a win.

The nuance most coverage skips

Three honest points sit underneath the headline. First, superiority was formally missed, so "Mounjaro is better for your heart" overstates what the trial proved. Second, the comparator was not a placebo but an already heart-protective drug, which is exactly why matching it still counts for something real. Third, the trial was funded by Eli Lilly, which makes both tirzepatide and dulaglutide, so both the drug and its comparator came from the same company. None of that makes the result fake. It just means the accurate summary is "as good as an existing heart-protective GLP-1," not "the new heart drug."

There is a more favourable number that made the rounds, and it deserves its correct label. A prespecified post hoc analysis in JAMA Cardiology looked at a broader six-part outcome that added heart-failure hospitalisation, coronary procedures and kidney events on top of MACE. On that wider measure tirzepatide did come out ahead: 23.7% versus 27.4%, a hazard ratio of 0.84 (95% CI 0.79 to 0.90). That is a genuine signal, but it is a secondary, after-the-fact analysis of a broader endpoint, not the primary MACE result the approval hangs on. Keep the two apart when you weigh what this drug does for the heart.

Does that make Mounjaro better than Ozempic for your heart?

This is the question spiking in search right now, and the honest answer is that SURPASS-CVOT cannot settle it. The trial never compared tirzepatide against semaglutide. Ozempic earned its own cardiovascular label from separate trials (SUSTAIN-6 and SELECT), where semaglutide cut heart events against placebo. Mounjaro earned its label by matching dulaglutide. Those are different comparisons against different drugs, so lining them up as "Mounjaro beat Ozempic" is not something any single trial has shown.

What you can say fairly is that both semaglutide and tirzepatide now have real cardiovascular evidence behind them in type 2 diabetes, which is reassuring if you are on either one. Which drug is right for a given person depends on their diabetes control, weight goals, side effects, cost and what their prescriber sees in their history, not on a headline about a single percentage point. If you want the fuller picture of how the two compare across outcomes, our overview of semaglutide and tirzepatide cardiovascular outcomes and the piece on semaglutide's heart benefits in the SELECT trial lay out what each drug's own trials found.

Side effects did not disappear

A heart indication does not erase the GLP-1 side effects you already know about. In SURPASS-CVOT, gastrointestinal complaints were more common on tirzepatide than on dulaglutide, in the region of 42% versus 36%. Nausea, diarrhoea, constipation and reflux are the usual culprits, and they tend to be worst while the dose is being increased. That daily reality matters, because the people most likely to benefit from the heart indication are often older, on several medications, and less able to shrug off weeks of feeling unwell. None of this is a reason to avoid a drug your doctor recommends. It is a reason to plan for the first few months rather than be surprised by them.

What this means if you take a GLP-1

The practical takeaways are calm and specific.

1. If you have type 2 diabetes and heart disease, this approval widens your options, and it is worth a conversation with your prescriber about whether tirzepatide fits your situation.
2. If you take Mounjaro or Zepbound for weight loss without diabetes, this label does not apply to you, and the trial did not study you, so do not read a heart claim into your own prescription.
3. Do not start, stop or switch any GLP-1 medication on the strength of a news story. The right drug is a clinical decision, not a marketing one.
4. Whatever GLP-1 you are on, the appetite drop that drives weight loss also shrinks how much food, and how many nutrients, you take in. That part is worth managing actively.

Nutrient support while your appetite is down

Here is where a supplement business has to be honest with you: no supplement protects your heart, lowers your MACE risk, or does anything the trial above measured. Anyone selling one that claims to is overselling. What supplements can reasonably do is help close the everyday nutrient gap that opens up when you eat far less. Cut several hundred calories a day for months and you cut your intake of the vitamins and minerals those calories carried, which is why nutrient deficiency on GLP-1 is a real and measurable pattern over time. The nutrients most often flagged are vitamin B12, vitamin D, iron and magnesium, plus enough protein to protect muscle.

If you are newly on Mounjaro for your heart and diabetes, the sensible move is to guard those basics while your clinician manages the medication. Our GLP-1 supplement protocol covers what to take and how much, and the companion guide on which vitamins to take and monitor pairs it with the blood tests worth asking for. GLP-1 Shield is built around the micronutrients people most often run low on while losing weight quickly, as a complement to good food and medical care, never a replacement for either.

Key takeaways

• The FDA approved Mounjaro on 28 August 2026 to reduce heart attack, stroke and cardiovascular death, but only in adults with type 2 diabetes and high cardiovascular risk.
• SURPASS-CVOT (13,299 people) showed tirzepatide was non-inferior to dulaglutide (HR 0.92), meaning as good as an already heart-protective GLP-1, not clearly better. Superiority was formally missed (P=0.09).
• A broader six-part post hoc measure in JAMA Cardiology favoured tirzepatide (HR 0.84), but that is a secondary analysis, not the primary MACE result.
• The trial did not compare Mounjaro against Ozempic, so it cannot answer which is better for the heart.
• The approval changes nothing about GLP-1 side effects or the nutrient gap from eating less. No supplement protects the heart; supplements only help cover micronutrient shortfalls.

Evidence current as of August 31, 2026. This article is general information, not medical advice. GLP-1 medications are prescription-only and should be used under medical supervision. Never start, stop or change a heart or diabetes medication based on a news story; talk to your prescriber about your own situation.

Frequently asked questions

Does Mounjaro protect your heart?

In adults with type 2 diabetes and high cardiovascular risk, yes, Mounjaro now has an FDA indication to reduce heart attack, stroke and cardiovascular death. In the SURPASS-CVOT trial (13,299 people), tirzepatide was non-inferior to dulaglutide, an older GLP-1 already proven to protect the heart. It matched that drug rather than clearly beating it, and it is not approved for heart protection in people without type 2 diabetes.

Is Mounjaro better than Ozempic for the heart?

No single trial has shown that. SURPASS-CVOT compared tirzepatide against dulaglutide (Trulicity), not against semaglutide (Ozempic). Ozempic earned its own cardiovascular label from separate placebo-controlled trials. Both drugs now have real heart evidence in type 2 diabetes, so which one suits you is a decision for your prescriber, not a matter of one headline.

Did the SURPASS-CVOT trial prove Mounjaro is superior?

No. The trial met its goal for non-inferiority (P=0.003) but missed the higher bar of superiority (P=0.09), with a hazard ratio of 0.92 whose confidence interval crossed 1.0. A separate broader six-part post hoc analysis in JAMA Cardiology did favour tirzepatide (HR 0.84), but that is a secondary analysis of a wider outcome, not the primary MACE result the approval is based on.

If I take Mounjaro for weight loss, does this approval apply to me?

Not directly. The heart indication is for adults with type 2 diabetes and high cardiovascular risk, and SURPASS-CVOT only studied people with diabetes and existing cardiovascular disease. If you use Mounjaro or Zepbound for weight loss without diabetes, the trial did not include you, so do not read a heart claim into your prescription. Focus on what you can control, including nutrient support while your appetite is reduced.